Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4
British Journal of Cancer 116, 620 (28 February 2017). doi:10.1038/bjc.2016.445
Authors: Susan Breslin, Michelle C Lowry & Lorraine O'Driscoll
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jDcCzV
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου